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Abstract
In  a  single  institution,  in  a  group  of  28  myeloma patients  deemed  eligible  for  autologous 
transplant, stem cell mobilization was attempted using filgrastim: 26 individuals were given 
31 autografts employing 1-4 (median three) apheresis sessions, to obtain a target stem cell 
dose of 1 x 10
6 CD34 +ve viable cells / Kg of the recipient. The median number of grafted 
CD34 cells was 7.56 x 10
6  / Kg of the recipient; the range being 0.92 to 
poor mobilizers individuals in which a cell collection of < 1 x 10
obtained, a subset of eight poor mobilizers was identified; in two patients the autograft was 
aborted because of an extremely poor CD34 +ve
Kg  of  the  recipient)  after  four  apheresis  sessions.  The  long
patients grafted with > 1 x 10
6 CD34 +ve viable cells / Kg was better (80% at 80 months) than 
those grafted with < 1 x 10
6 CD34 +ve viable cells / Kg (67% at 76 months). Methods to 
improve stem cell mobilization are needed and may result in obtaining better results when 
autografting multiple myeloma patients.
Introduction:  High-dose  chemotherapy  followed 
by  autologous  stem  cell  transplantation  (SCT)  is 
considered  standard  of  care  for  patients  with 
multiple  myeloma  (MM).
1,2 In  this  setting, 
autologous peripheral blood stem cells (PBSC) have 
largely  replaced  autologous  bone  marrow  as  the 
source  of  stem  cells.  Advantages  of  autologous 
PBSC grafts over bone marrow grafts include faster 
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In  a  single  institution,  in  a  group  of  28  myeloma patients  deemed  eligible  for  autologous 
transplant, stem cell mobilization was attempted using filgrastim: 26 individuals were given 
4 (median three) apheresis sessions, to obtain a target stem cell 
CD34 +ve viable cells / Kg of the recipient. The median number of grafted 
/ Kg of the recipient; the range being 0.92 to 14.8.  By defining as 
poor mobilizers individuals in which a cell collection of < 1 x 10
6 CD34 viable cells / Kg was 
obtained, a subset of eight poor mobilizers was identified; in two patients the autograft was 
aborted because of an extremely poor CD34 +ve cell yield (< 0.2 x 10
6 CD34 +ve viable cells / 
Kg  of  the  recipient)  after  four  apheresis  sessions.  The  long-term  overall  survival  of  the 
CD34 +ve viable cells / Kg was better (80% at 80 months) than 
CD34 +ve viable cells / Kg (67% at 76 months). Methods to 
improve stem cell mobilization are needed and may result in obtaining better results when 
autografting multiple myeloma patients.
dose  chemotherapy  followed 
by  autologous  stem  cell  transplantation  (SCT)  is 
considered  standard  of  care  for  patients  with 
In  this  setting, 
autologous peripheral blood stem cells (PBSC) have 
largely  replaced  autologous  bone  marrow  as  the 
source  of  stem  cells.  Advantages  of  autologous 
PBSC grafts over bone marrow grafts include faster 
engrafment after high-dose chemotherapy, re
contamination  with  tumor  cells
morbidity and mortality.
3-5
Hematopoietic  stem  cell  mobilization  is 
generally  accomplished  by  administration  of 
hematopoietic  growth  factors  like  granulocyte 
colony    stimulating  factor  (G
combination  of  myelosuppressive  chemotherapy 
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In  a  single  institution,  in  a  group  of  28  myeloma  patients  deemed  eligible  for  autologous 
transplant, stem cell mobilization was attempted using filgrastim: 26 individuals were given 
4 (median three) apheresis sessions, to obtain a target stem cell 
CD34 +ve viable cells / Kg of the recipient. The median number of grafted 
14.8.  By defining as 
CD34 viable cells / Kg was 
obtained, a subset of eight poor mobilizers was identified; in two patients the autograft was 
CD34 +ve viable cells / 
term  overall  survival  of  the 
CD34 +ve viable cells / Kg was better (80% at 80 months) than 
CD34 +ve viable cells / Kg (67% at 76 months). Methods to 
improve stem cell mobilization are needed and may result in obtaining better results when 
dose chemotherapy, reduced 
contamination  with  tumor  cells
3 and  lower 
Hematopoietic  stem  cell  mobilization  is 
generally  accomplished  by  administration  of 
hematopoietic  growth  factors  like  granulocyte 
colony    stimulating  factor  (G-CSF)
1-5 or  a 
tion  of  myelosuppressive  chemotherapy Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
and  hematopoietic  growth  factors.  A  number  of 
factors have been reported to impact progenitor cell 
mobilization  but  the  predictive  factors  vary  from 
one study to the other.
The  purpose  of  this  study  is  to  analyze  the 
prevalence of poor mobilization in individuals with 
MM, prospectively studied and grafted in a single 
institution using the same autografting procedure.
Patients and Methods:
a)  Patients: Patients  with  MM  diagnosed  and 
autografted  at  the  Centro  de  Hematología  y 
Medicina Interna de Puebla, a part of the Clínica 
RUIZ, in Puebla, México between August 1993 to 
September 2008 were prospectively included in the 
study.  The  diagnosis  of  MM  was  based  on  the 
following findings:
1-2,4 a) Increased numbers (more 
than  30%)  of  abnormal,  atypical  or  immature 
plasma cells in the bone marrow or histologic proof 
of  plasmacytoma; b)  presence of  an M-protein in 
the serum or  urine;  or  c) Bone lesions consistent 
with those of  multiple myeloma. Individuals with 
plasma cell reactions to connective tissue disorders, 
liver  disease,  metastatic  carcinoma  or  chronic 
infections  were  not  included,  nor  patients  with 
monoclonal  gammopathy  of  undetermined 
significance,
3 smoldering  multiple  myeloma, 
solitary  plasmacytoma  or  plasma  cell  leukemia. 
Individuals  with  primary  amyloidosis  (AL)  were 
included  only  if  features  of  MM predominated.
6,7
All  patients  were  autografted  in  the  Centro  de 
Hematología  y  Medicina  Interna  de  Puebla, 
México, and had received a median of 4 (range 1-7) 
prior  chemotherapy  regimens  (Table  1).  Normal 
renal  and  liver  function  tests  were  needed  for 
inclusion  as  well  as  informed  consent  approved 
before any procedure.
b)  PBSC  mobilization  and  apheresis: The  PBSC 
mobilization schedule was started at least 30 days 
after the last dose of chemotherapy. Subcutaneous 
G-CSF (10 ug / Kg / day / 5 days) was given for 
mobilization of stem cells, starting day - 7. Using 
either  a  peripheral  vein  or  a  Majurkar-type 
subclavian catheter, the apheresis procedures were 
performed on days – 4 – 3, – 2 and – 1, using a 
Haemonetics  V-50  PLUS  machine  (Haemonetics 
Corporation,  Braintree  MA)  or  a  Baxter C-3000 
PLUS  machine  (Baxter Healthcare,  Deerfield  IL), 
and the Spin-Nebraska protocol.
8 The endpoint of 
collection was the processing of 5000 - 7000 ml of 
blood / m
2 in each of the apheresis procedures, in 
order to obtain at least 3 x 10
8 mononuclear cells 
and  /  or  1  x  10
6 viable  CD34  cells  /  Kg  of  the 
recipient’s weight.
1,3-5
c)  Conditioning  and  autografting: Intravenous 
melphalan,  200  mg/m
2 in  a  single  I.V.  dose  was 
used on day  – 1 in all patients. Ondansetron (8 mg 
i.v. every 12 h after chemotherapy), ciprofloxacin 
(250 mg. bid) and fluconazole (200 mg bid) were 
used in all patients. G-CSF (10 ug / Kg / day / 5 
days)  was  re-started  on  day  +5  and  used    until 
granulocytes  were  greater  than  0.5  x  10
9/L. 
Antibiotics  and  antimycotics  were  used  until 
granulocytes were above 0.5 x 10
9/L. All patients 
had daily laboratory workup and clinical studies.
d)  Apheresis  product  preservation,  studies  and 
infusion: The products  of  the apheresis  and  1  ml 
aliquots were kept  in ACD-A (Baxter Healthcare, 
Deerfield  IL)  at  4
oC,  in  300  ml  transfer  packs 
(Baxter Healthcare, Deerfield IL) composed of gas
impermeable, polyvinyl chloride plastic film for up 
to  96  hours.  Enumeration  of  the  total  white 
mononuclear cells (MNC) and CD34 +ve cells was 
done  by  flow-cytometry
9 in  an  EPICS  Elite  ESP 
apparatus (Coulter Electronics, Hialeah, FL), using 
for  the  latter subpopulation  the  anti-CD34 
monoclonal antibody HPCA-2 (Becton Dickinson, 
San José CA), gating in propidium iodide-excluding 
CD45(+)  MNC  population  according  to  forward 
and 90° angle light scattering. Additional viability 
studies  of  the  MNC  prior  to  its  re-infusion  used 
propidium iodide exclusion and anti-cell antibodies 
on a flow cytometer. No purging procedures were 
performed. The apheresis products obtained on days  
– 4, – 3, – 2 and – 1 were reinfused to the patients 
on days 0, +1, +2 and +3 respectively after keeping 
them in the conventional blood bank refrigerator at 
4 degress centigrade.
3,4
e)  Criteria  for  assesment  of  the  mobilization 
procedures: One  to  four  apheresis  sessions  were 
performed to obtain a target stem cell dose of 1 x 
10
6 CD34  +ve viable  cells /  Kg  of  the  recipient. 
Cases in which less than this amount of CD34 +ve 
progenitor cells were obtained after four apheresis 
sessions were classified as “poor” mobilizers.
f) Response assessment: Very good partial response 
(VGPR) was defined as a decrease of 90% in the 
serum paraprotein level. Partial remission (PR) as a 
decrease of 50% in the serum paraprotein level, and 
minimal response (MR) as a decrease of 25% in the 
serum paraprotein level.
1
Results:
a) Patients: All patients with multiple myeloma less 
than  70  years  are  offered  an  autograft  in  ourMedit J Hemat Infect Dis 2010; 2(2): Open Journal System
Table  1.  Salient  features  of  the  31  autografts  divided  into  two  groups  according  to  the  number  of  hematopoietic  stem  cells 
autografted.
n
Transplants 31
Patients 26
CD34 +ve MNC grafted
< 1 x 10
6 /kg > 1 x 10
6 /kg
Transplants 6 25
Age
Median Range Median Range
54 43 – 65 55 44 – 66
Paraprotein
IgG 5 15
IgA 1 6
Light chaín only 0 2
Non secretory 0 2
Apheresis sessions
Median Range Median Range
3 3 – 4 3 2 – 4
Previous treatment:
Thal / Dex 1 (16%) 6 (24%)
VAD 0 10
Bortezomib 4 (66%) 6 (24%)
Oral melphalan 2 (33%) 3 (12%)
Autograft 2 (33%) 2 (8%)
Others 1 3
Overall survival 67% at 76 mos. 80% at 80 mos.
MNC = mononuclear cells; Thal = thalidomide, Dex = dexametasone; VAD = vincristine, adriamycyn and dexametasone; mos = 
months.
institution;  28  consecutive  patients  were  deemed 
eligible  for  autologous  transplant  and  attempted 
stem cell mobilization; there were 13 females and 
15 males. Since our autografting procedure does not 
involve  hematopoietic  stem  cell  freezing,
1,4-5 the 
procedure was aborted if  less than 0.5 x 10
6 CD34 
+ve viable cells / Kg of the recipient were collected; 
accordingly,  the  autograft  was  aborted  in  two 
patients because of a very poor CD34 +ve cell yield 
(less than 0.2 x 10
6 CD34 +ve viable cells / Kg of 
the  recipient)  after  four  apheresis  sessions;  one 
patient  had  developed  an  acute  myelogenous 
leukemia  after  being  treated  with  oral  melphalan 
during  51  months  and  failed  to  mobilize  after 
entering a complete remission of the leukemia; he 
was  later  on  given  an  allogeneic  graft  with 
umbilical  cord  cells  and  remains  disease-free  75 
months after attempting the autograft.
10 The other 
patient  had  received  an  autologous  graft  using 
intravenous melphalan 51 months before attempting 
the second autograft; after failing mobilization with 
G-CSF he was later on mobilized with G-CSF plus 
plerixafor  and  subsequently  re-autografted
succesfully.
11
In  the  group  of  26  patients  who  were 
autografted, the median age was 54 years (range 42 
to 66). The type of paraprotein was IgG in 16 cases, 
IgA in 6 cases, light chain disease in 2 cases (both 
kappa).  According  to  the  International  Staging 
System (ISS),
12 21  patients  were  in  stage  I,  3  in 
stage II and 2  in stage III. All patients had been 
treated before the autograft: Six with thalidomide / 
dexametasone  (thal/dex), 11  with  bortezomib-
containing regimens, 9 with vincristine / adriamycin 
/ dexamethasone (VAD) and 5 with other schedules. 
No patient had received radiation therapy as part of 
the  previous  treatment  and  in  all  cases  the 
autologous graft was performed as part of the initial 
therapy. 
b) PBSC mobilization and apheresis: A median of 
three  apheresis  sessions  were  needed  to  collect  a 
minimum of 1 x 10
6 CD34 +ve viable cells / Kg of 
the  recipient;
1 the  range  was  2  to  4  sessions  toMedit J Hemat Infect Dis 2010; 2(2): Open Journal System
Figure  1.  Overall  survival  of  the  26  multiple  myeloma patients  given  31  autografts, and  divided  according to  the  number  of 
hematopoiteic stem cells autografted (more or less than 1 x 10
6 CD34 +ve viable cells / Kg of the recipient). The differences are not 
statistically significant.
obtain enough CD34 +ve cells. Circulating CD34 
+ve    cells  were  not  enumerated  prior  to  the 
apheresis procedures.
c) Conditioning and autografting: All patients were 
conditioned  with  a  single  dose  of  intravenous 
melphalan, 200 mg/ m
2. In cases in which less than 
1 x 10
6 CD34 +ve viable cells / Kg of the recipient, 
defined as poor mobilizers, the dose of melphalan 
was  adjusted  to  180  mg/m
2 (90%  of  the  planned 
dose).
d) Apheresis product studies: The median number 
of transplanted CD34 +ve viable cell was 7.56 x 10
6
CD34  +ve  viable  cells  /  Kg  of  the  recipient;  the 
range was 0.92 to 14.8. In all cases the viability of 
the  CD34  cells  was  above  85%  prior  to  being 
reinfused to the patients. 
e) Assesment of the mobilization procedures: One to 
four  (median  three)  apheresis  sessions  were 
performed to obtain a target stem cell dose of 1 x 
10
6 CD34 +ve viable cells / Kg of the recipient. In 
six cases, less than 1 x 10
6 CD34 +ve viable cells / 
Kg of the recipient were obtained, in 16 cases 1 to 2 
x 10
6 CD34 +ve viable cells / Kg of the recipient, 
whereas in 9 cases more than 2 x 10
6 CD34 +ve 
viable cells / Kg of the recipient.
f) Engraftment and response: In the whole group of 
patients, the time to achieve more than 0.5 x 10
9/L 
granulocytes had a median of 27 days (range 0 to 
53),  whereas  the time  to recover more  than  20  x 
10
9/L platelets had a median of 37 days (range 0 to 
73). Of the 26 patients autografted, 19 achieved a 
complete remission, 6 a very good partial remission, 
5 a partial remission and one a minor response. The 
100-day mortality was 9.6% (3 of 31 transplants); 
Two patients died at day +9 and +11 as a result of 
sepsis during granulocytopenia and one died at day 
+100  due  to  a  myocardial  infarction;  they  had 
received 2.5,  1.5 and 3.4 x 10
6 CD34 +ve viable 
cells / Kg, respectively. The overall median post-
transplant survival (OS) has not been reached, being 
above  80  months,  whereas  the  80-month  OS  is 
77%.  Relapses  presented  in  11/31  autografts,  a 
median  of  34  months  after  the  procedure;  five 
patients were rescued with a second autograft and 
two were given an allogeneic grafts. The autograft 
procedure was started in an outpatient basis in all 
instances, however four patients where admitted to 
the  hospital  as  a  result  of:  amebic  colitis, 
Pseudomona  aeruginosa sepsis,  cerebrovascular 
episode and soft-tissue abscess, one case each.
In the whole group of 31 autografts, a subset of 
six  poor  mobilizers  was  identified.  The  table  1
shows the salient data of these six poor mobilizers Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
compared with those of the 25 autografts in which a 
better  mobilization  was  obtained.  It  is  interesting 
that the long-term overall survival of the multiple 
myeloma  patients  allografted  with  more  than  1  x
10
6 CD34 +ve viable cells / Kg was better (80% at 
80 months) than those autografted with less than 1 x 
10
6 CD34 +ve viable cells / Kg (67% at 76 months); 
the  differences  however  are  not  statistically 
significant  according  to  the  log-rank  chi  square 
method most likely as a result of the low number of 
patients  included  in  the  study,  see  table  1 and 
figure 1. There were not significant differences in 
time to recover granulocytes and platelets between 
patients receiving more or less than 1 x 10
6 CD34 
+ve viable cells / Kg.
Discussion: A  number  of  factors  have  been 
reported  to  impact  stem  cell  mobilization.  These 
include  patient  age,  weight,  diagnosis,  type  and 
number  of  prior  chemotherapeutic  regimens 
administered,  bone  marrow  involvement  with  the 
malignancy at baseline, extent of cell recovery from 
previous  chemotherapy  at  the  time  of  starting 
mobilization treatment, prior radiation therapy, time 
from  diagnosis  to  harvest,  and  disease  status.
13-15
Other factors include type of cytokine used and type 
and  dose  of  chemotherapy  regimen,  if  any,  for 
mobilization.
13-15
The number of CD34 +ve hematopoietic stem 
cells required to successfully conduct an autograft 
has  not  been  clearly  defined.  Some  authors  have 
described  that  a  minimum  of  2  x  10
6 CD34  +ve 
viable  cells  / Kg  of  the  recipient  is  required  to 
rescue the hematopoiesis of the patient.
13 We have 
shown that a minimum of 1 x 10
6 CD34 +ve viable 
cells  /  Kg  of  the  recipient  may  be  useful  to 
successfully  autograft  patients  with  multiple 
myeloma
1 or  other  diseases.
3-4 This  apparent 
discrepancy may stem from several factors, one of 
them being the enumeration methods: we have also 
shown  previously  that  a  considerable  variation 
might be due to the selection of antibodies, staining 
protocols,  and  acquisition  strategies  for the  flow 
cytometric  enumeration  of  these  cells  which  may 
account even for two-fold differences;
16 both inter-
instrument  and  inter-protocol  variation  provide 
explanation  for  the  redundantly  reported 
discrepancies  concerning  the  numbers  of  CD34 
cells  that  suffice to  secure  hematopoietic  grafting 
and  to  define  poor  mobilizers.
16 Accordingly,  the 
exact incidence of poor mobilizers in the setting of 
autologous grafting is unknown and has varied in 
the literature between 5 to 40% in different subsets 
of  patients.
13 Using  a  lower  threshold,  we  have 
found a prevalence of 24% (8 of 33 autografts) of 
poor mobilizers, which only in two cases led into 
aborting  the  autografting  procedure.  With  the 
limitations of a small study, we found that certain 
features  of  the  patients  and/or  disease  were 
associated with a defective mobilization: Previous 
treatment  with  oral  melphalan,  previous  autograft 
with intravenous melphalan and previous treatment 
with  bortezomib.  The  low  number  of  patients 
included in each subset of treatments makes hard to 
know  of  prior  exposure  to  certain  drugs  per  se
interfered  with  mobilization,  or  whether  patients 
exposed  to  some  agents  had  other  features  that 
would compromise mobilization. On the other hand, 
it should be mentioned that some patients who had 
been treated previously with oral melphalan could 
be successfully autografted; accordingly, we believe 
that attempts of autografting should be tried even in 
patients previously treated with oral melphalan. 
In order to improve the mobilization techniques 
for stem cell autografting, several approaches have 
been tried. The mobilization seems to be better if 
both  chemotherapy  and  growth  factors  are 
employed.
17 Recently,  Dugan  et  al. showed  that 
plerixafor  can  safely  be  added  to  chemotherapy-
based mobilization  regimens  and  may  accelerate 
the rate of increase in CD34 +ve cells on the second 
day  of  apheresis
18 whereas  Di  Persio  et  al. have 
shown  similar  results  in  patients  with  multiple 
myeloma.
19 Further  studies  are  warranted 
to evaluate  the  effect  of  this  drug  in  combination 
with chemomobilization  on  stem cell  mobilization 
and collection on the first and subsequent days of 
apheresis, and its impact on resource utilization and 
results  improvement.
19,20 Since  there  are  data 
suggesting that failure of mobilization in myeloma 
patients results in increased expenses and increased 
use of resources,
21 methods to predict the failure to 
mobilize have been suggested.
22 Studies to analyze 
the balance of the costs of improved mobilization 
methods and the costs of failing to mobilize patients 
with  myeloma  who  are  to  be  autografted  are 
mandatory to further explore this field, specially in 
developing  countries,  where  autografting  patients 
with multiple myeloma is still a cheaper therapeutic 
option  than  the  use  of  the  novel  anty-myeloma 
drugs.
23
Conclusions: In summary, we have found that in 
patients with multiple myeloma, using a threshold 
of  1  x  10
6 CD34  +ve  viable  cells  /  Kg  of  the 
recipient  has  allowed  us  to  define  a  suboptimal 
mobilization  which  presents  in  one  quarter  of 
patients and seems to be associated with previous 
treatment  with  oral  melphalan,  previous  autograft 
with intravenous melphalan and previous treatment Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
with  bortezomib,  and  that  the  long  term  overall 
survival of the poor mobilizers seems to be worse 
than that of individuals grafted with 1 x 10
6 CD34 
+ve  viable  cells  /  Kg  of  the  recipient.  Efforts 
directed to improve stem cell mobilization seem to 
be  warranted  and  could  result  in  improving  the 
results of autografting and the prognosis of patients 
with multiple myeloma.
24
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